<DOC>
	<DOC>NCT01924195</DOC>
	<brief_summary>Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of andvanced non-small cell lung cancer who failed two lines of chemotherapy</brief_summary>
	<brief_title>Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>1. pathology diagnosed with advanced NSCL with measurable lesions; 2. Have failed for 2 lines of chemotherapy; 3. 1870years,ECOG PS:02,Life expectancy of more than 3 months; 4. Other cytotoxic drugs,radiation therapy,or surgery≥4 weeks; 5. main organs function is normal; 6. must be agreed to take contraceptive measures during the study and within 6 months after end. 1. SCLC(including mixed with NSCLC); 2. the central cavity of Squamous cell carcinoma and hemoptysis with NSCLC; 3. patients failed to use the antitumor angiogenesis therapy; 4. patients has many influence factors toward oral medications ; 5. Brain metastases patients accompanied by symptoms or symptom control for less than two months; 6. patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG)&gt;10mmol/L);urine protein≥++,etc. 7. patients failed to heal wounds or fractures for Longterm; 8. 4 weeks before enrollment, patients appeared NCI CTC AE grading &gt;1 pulmonary hemorrhage; 4 weeks before enrollment, patients who appeared NCI CTC AE grade&gt; 2 have other parts of the bleeding; patients has a tendency to bleed (eg active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy such as warfarin, heparin or its analogues; 9. patients occurred venous thromboembolic events within 6 months; 10. patients has HIVpositive or organ transplantation;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>lung</keyword>
	<keyword>Anlotinib</keyword>
	<keyword>AL3818</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Cancer</keyword>
</DOC>